Karyopharm Therapeutics Inc. (KPTI)
KPTI Stock Price Chart
Explore Karyopharm Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze KPTI price movements and trends.
KPTI Company Profile
Discover essential business fundamentals and corporate details for Karyopharm Therapeutics Inc. (KPTI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Nov 2013
Employees
279.00
Website
https://www.karyopharm.comCEO
Richard A. Paulson
Description
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
KPTI Financial Timeline
Browse a chronological timeline of Karyopharm Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$1.31, while revenue estimate is $33.12m.
Earnings released on 14 May 2026
EPS came in at -$1.24 surpassing the estimated -$1.45 by +14.48%, while revenue for the quarter reached $35.07m , beating expectations by +11.68%.
Earnings released on 12 Feb 2026
EPS came in at -$2.23 surpassing the estimated -$2.26 by +1.33%, while revenue for the quarter reached $34.08m , missing expectations by -2.92%.
Earnings released on 3 Nov 2025
EPS came in at -$3.82 falling short of the estimated -$3.47 by -10.09%, while revenue for the quarter reached $44.04m , beating expectations by +4.71%.
Earnings released on 11 Aug 2025
EPS came in at -$4.32 falling short of the estimated -$3.80 by -13.68%, while revenue for the quarter reached $37.93m , missing expectations by -4.13%.
Earnings released on 12 May 2025
EPS came in at -$2.77 surpassing the estimated -$4.21 by +34.20%, while revenue for the quarter reached $30.02m , missing expectations by -14.54%.
Stock split effective on 26 Feb 2025
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 19 Feb 2025
EPS came in at -$3.60 surpassing the estimated -$3.90 by +7.69%, while revenue for the quarter reached $30.54m , missing expectations by -19.26%.
Earnings released on 5 Nov 2024
EPS came in at -$3.90 surpassing the estimated -$4.05 by +3.70%, while revenue for the quarter reached $38.78m , beating expectations by +1.54%.
Earnings released on 6 Aug 2024
EPS came in at -$3.00 surpassing the estimated -$4.35 by +31.03%, while revenue for the quarter reached $42.79m , beating expectations by +18.26%.
Earnings released on 8 May 2024
EPS came in at -$4.80 surpassing the estimated -$4.95 by +3.03%, while revenue for the quarter reached $33.13m , missing expectations by -3.90%.
Earnings released on 29 Feb 2024
EPS came in at -$5.40 falling short of the estimated -$4.35 by -24.14%, while revenue for the quarter reached $33.75m , missing expectations by -4.67%.
Earnings released on 2 Nov 2023
EPS came in at -$4.50 falling short of the estimated -$4.20 by -7.14%, while revenue for the quarter reached $36.01m , missing expectations by -3.41%.
Earnings released on 2 Aug 2023
EPS came in at -$4.35 surpassing the estimated -$5.10 by +14.71%, while revenue for the quarter reached $37.58m , beating expectations by +4.36%.
Earnings released on 4 May 2023
EPS came in at -$4.50 surpassing the estimated -$5.10 by +11.76%, while revenue for the quarter reached $38.70m , beating expectations by +5.73%.
Earnings released on 15 Feb 2023
EPS came in at -$6.45 falling short of the estimated -$5.10 by -26.47%, while revenue for the quarter reached $33.58m , missing expectations by -2.46%.
Earnings released on 3 Nov 2022
EPS came in at -$6.75 surpassing the estimated -$8.40 by +19.64%, while revenue for the quarter reached $36.15m , beating expectations by +3.78%.
Earnings released on 4 Aug 2022
EPS came in at -$9.30 surpassing the estimated -$9.45 by +1.59%, while revenue for the quarter reached $39.68m , beating expectations by +10.33%.
Earnings released on 5 May 2022
EPS came in at -$7.95 surpassing the estimated -$9.45 by +15.87%, while revenue for the quarter reached $47.67m , beating expectations by +38.54%.
Earnings released on 8 Feb 2022
EPS came in at $6.90 surpassing the estimated -$6.00 by +215.00%, while revenue for the quarter reached $126.27m , beating expectations by +139.54%.
Earnings released on 3 Nov 2021
EPS came in at -$10.34 falling short of the estimated -$10.19 by -1.47%, while revenue for the quarter reached $37.69m , beating expectations by +46.08%.
Earnings released on 5 Aug 2021
EPS came in at -$10.64 surpassing the estimated -$10.79 by +1.39%, while revenue for the quarter reached $22.60m , meeting expectations.
KPTI Stock Performance
Access detailed KPTI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
